Decline in Varicella-Related Ambulatory Visits and Hospitalizations in the United States Since Routine Immunization Against Varicella

Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
The Pediatric Infectious Disease Journal (Impact Factor: 2.72). 11/2009; 29(3):199-204. DOI: 10.1097/INF.0b013e3181bbf2a0
Source: PubMed


Widespread varicella vaccination has led to substantial decreases in varicella-related mortality and hospitalizations. The effect of the vaccine on ambulatory care utilization is poorly defined.
To determine trends in varicella-related ambulatory care and hospital discharges before and after vaccine licensure.
Estimates of varicella-related ambulatory and hospital discharges were calculated for the pre- (1993-1995) and post- (1996-2004) vaccine licensure periods using the National Ambulatory Medical Care Survey, National Hospital Ambulatory Medical Care Survey, and National Hospital Discharge Survey.
Ambulatory and hospital discharge rates for varicella.
The rate of varicella-related ambulatory discharges decreased by 66% from 106.6 per 100,000 (95% confidence interval [CI]: 80.5-132.6) in the prelicensure period to 36.4 per 100,000 population (95% CI: 29.3-43.5) in the post-licensure period (P < 0.001). The decrease was significant across all age groups <45 years, with the greatest reduction (98%) occurring among patients 0 to 4 years of age. The incidence of varicella-related hospital discharges decreased by 53% from 30.9 per 100,000 (95% CI: 24.4-37.3) to 14.5 per 100,000 population (95% CI: 12.1-16.8; P < 0.001). This difference was significant among patients <14 years of age. Rates of varicella-related ambulatory discharges decreased significantly for both whites and non-whites in the postlicensure period, but postlicensure ambulatory discharge rates remained higher for non-whites than for whites. Decreases in varicella-related hospital discharges were statistically significant for whites and non-whites. Racial differences in the incidence of varicella-related hospital discharges also persisted following vaccine licensure.
Varicella-related ambulatory visits and hospitalizations have decreased significantly in the period after licensure of the varicella vaccine.

Download full-text


Available from: Sarah Wood, Apr 07, 2015
  • Source
    • "Moreover, during the first decade after varicella implementation a significant decrease in varicella associated morbidity , hospitalization and mortality were noted [Davis et al. 2004; Marin et al. 2011; Nguyen et al. 2005; Shah et al. 2010; Zhou et al. 2005]. Ambulatory visits due to varicella significantly decreased by 66% from 106.6 to 36.4/100,000 population and as expected this was mostly evident in the age group mainly affected, i.e. young children 1–4 years old [Shah et al. 2010]. Moreover, hospitalization rates decreased significantly [Dubos et al. 2007; Reynolds et al. 2008; Zhou et al. 2005]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Varicella is a highly contagious disease caused by primary infection with varicella zoster virus (VZV). VZV infection, as well as varicella vaccination, induces VZV-specific antibody and T-cell-mediated immunity, essential for recovery. The immune responses developed contribute to protection following re-exposure to VZV. When cell-mediated immunity declines, as occurs with aging or immunosuppression, reactivation of VZV leads to herpes zoster (HZ). It has been almost 20 years since universal varicella vaccination has been implemented in many areas around the globe and this has resulted in a significant reduction of varicella-associated disease burden. Successes are reviewed here, whilst emphasis is put on the challenges ahead. Most countries that have not implemented routine childhood varicella vaccination have chosen to vaccinate high-risk groups alone. The main reasons for not introducing universal vaccination are discussed, including fear of age shift of peak incidence age and of HZ incidence increase. Possible reasons for not observing the predicted increase in HZ incidence are explored. The advantages and disadvantages of universal vs targeted vaccination as well as different vaccination schedules are discussed.
    Full-text · Article · Mar 2014
  • Source
    • "The number of recurrent infections in an individual with HSV is highly variable, whereas reactivation of VZV is seldom observed more than once or twice over the course of a lifetime. The natural history of VZV has been dramatically altered by the availability of vaccines directed at preventing varicella or chickenpox, the primary disease (Shah et al. 2010), and zoster or shingles, the reactivated form of the disease (Oxman et al. 2005). An effective vaccine directed against with HSV-1 or HSV-2 has yet to be delivered to the human population to prevent either primary or reactivated disease or as a therapeutic modality (Chentoufi et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Herpes simplex virus type 1 (HSV-1) is capable of causing a latent infection in sensory neurons that lasts for the lifetime of the host. The primary infection is resolved following the induction of the innate immune response that controls replication of the virus until the adaptive immune response can clear the active infection. HSV-1-specific CD8(+) T cells survey the ganglionic regions containing latently infected neurons and participate in preventing reactivation of HSV from latency. The long-term residence and migration dynamics of the T cells in the trigeminal ganglia appear to distinguish them from the traditional memory T cell subsets. Recently described tissue resident memory (TRM) T cells establish residence and survive for long periods in peripheral tissue compartments following antigen exposure. This review focuses on the immune system response to HSV-1 infection. Particular emphasis is placed on the evidence pointing to the HSV-1-specific CD8(+) T cells in the trigeminal belonging to the TRM class of memory T cells and the role of TRM cells in virus infection, pathogenesis, latency, and disease.
    Full-text · Article · Aug 2013 · Journal of NeuroVirology
  • Source
    • "The United States was the first country to implement routine varicella immunization for all children in 1995. Vaccination coverage in children 19-35 months of age reached 85% by 2003, and one-dose immunization was highly effective in reducing varicella-associated morbidity, ambulatory visits, hospitalisations and mortality, including indirect benefits observed in non-vaccinated groups [e.g., [14-17]. However, varicella outbreaks were still observed even in populations with high vaccination coverage; hence, the recommendations were expanded to a routine two-dose schedule in 2006 [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In 2004, routine varicella vaccination was recommended in Germany for children 11-14 months of age with one dose, and since 2009, with a second dose at 15-23 months of age. The effects on varicella epidemiology were investigated. Data on varicella vaccinations, cases and complications were collected from annual parent surveys (2006-2011), monthly paediatric practice surveillance (Oct 2006 - Sep 2011; five varicella seasons) and paediatric hospital databases (2005-2009) in the area of Munich (about 238,000 paediatric inhabitants); annual incidences of cases and hospitalisations were estimated. Varicella vaccination coverage (1st dose) in children 18-36 months of age increased in two steps (38%, 51%, 53%, 53%, 66% and 68%); second-dose coverage reached 59% in the 2011 survey. A monthly mean of 82 (62%) practices participated; they applied a total of 50,059 first-dose and 40,541 second-dose varicella vaccinations, with preferential use of combined MMR-varicella vaccine after recommendation of two doses, and reported a total of 16,054 varicella cases <17 years of age. The mean number of cases decreased by 67% in two steps, from 6.6 (95%CI 6.1-7.0) per 1,000 patient contacts in season 2006/07 to 4.2 (95%CI 3.9-4.6) in 2007/08 and 4.0 (95%CI 3.6-4.3) in 2008/09, and further to 2.3 (95%CI 2.0-2.6) in 2009/10 and 2.2 (95%CI 1.9-2.5) in 2010/11. The decrease occurred in all paediatric age groups, indicating herd protection effects. Incidence of varicella was estimated as 78/1,000 children <17 years of age in 2006/07, and 19/1,000 in 2010/11. Vaccinated cases increased from 0.3 (95%0.2-0.3) per 1,000 patient contacts in 2006/07 to 0.4 (95%CI 0.3-0.5) until 2008/09 and decreased to 0.2 (95%CI 0.2-0.3) until 2010/11. The practices treated a total of 134 complicated cases, mainly with skin complications. The paediatric hospitals recorded a total of 178 varicella patients, including 40 (22.5%) with neurological complications and one (0.6%) fatality due to varicella pneumonia. Incidence of hospitalisations decreased from 7.6 per 100,000 children <17 years of age in 2005 to 4.3 in 2009, and from 21.0 to 4.7 in children <5 years of age. Overall, the results show increasing acceptance and a strong impact of the varicella vaccination program, even with still suboptimal vaccination coverage.
    Full-text · Article · Jul 2013 · BMC Infectious Diseases
Show more